Related Experiment Videos
Therapy of malignancy-associated hypercalcemia: 1983
The American Journal of Medicine
|March 1, 1983
Summary
Hypercalcemia in cancer patients often stems from bone resorption. Treatments focus on reducing tumor burden, increasing calcium excretion, and inhibiting bone breakdown, with promising results from diphosphonates.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Hypercalcemia is a frequent complication in cancer patients.
- It can arise from tumor-secreted factors or skeletal metastases, both leading to osteoclastic bone resorption.
Purpose of the Study:
- To outline therapeutic strategies for managing hypercalcemia in cancer.
- To review current and emerging treatments targeting osteoclastic bone resorption.
Main Methods:
- Initial therapy involves hydration with saline and furosemide to enhance renal calcium clearance.
- Oral phosphorus is indicated for hypophosphatemic patients.
- Other treatments include glucocorticoids, calcitonin, prostaglandin synthetase inhibitors, and mithramycin.
Main Results:
- Diphosphonates, a new class of drugs, show promising results in clinical trials for malignancy-associated hypercalcemia.
- Dichloromethylene diphosphonate has demonstrated particularly encouraging outcomes.
Conclusions:
- Effective management of cancer-related hypercalcemia requires a multi-pronged approach.
- Inhibiting osteoclastic bone resorption is a key therapeutic goal, with diphosphonates emerging as a significant advancement.